33.24 USD
↗ 1.51 (4.76%)AT CLOSE (11:59 AM EDT)
NewAmsterdam Pharma Company N.V. Ordinary Shares
NAMSNASDAQ • USD
33.20
↘ 0.04 (0.12%)
POST MARKET (AS OF 07:59 PM EDT)
Post Market
AS OF 07:59 PM EDT
33.20
↘ 0.04 (0.12%)
Market: CLOSED
Shares of NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) are trading at $33.24. Our models show a "Buy" technical signal alongside a "Neutral" fundamental rating. Key drivers include a robust Altman Z-Score, a weak Piotroski F-Score of 1/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. Furthermore, NAMS is currently richly valued, trading at a premium to sector peers across key valuation metrics.
Technical & fundamental data as of Jun 26, 2026.
Open?$31.56
High?$33.41
Low?$31.56
Prev. Close?$31.73
Volume?1.6M
Avg. Volume?1.3M
VWAP?$32.97
Rel. Volume?1.20x
Bid / Ask
Bid?$28.43 × 100
Ask?$39.88 × 100
Spread?$11.45
Midpoint?$34.16
Valuation & Ratios
Market Cap?3.9B
Shares Out?116.9M
Float?62.2M
Float %?53.2%
P/E Ratio?N/A
P/B Ratio?5.84
EPS?-$1.82
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
Employees
100
Market Cap
3.7B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2022-11-23
Address
GOOIMEER 2-35
NARRDEN, P7 1411 DC
Phone: 35 206 2971
NARRDEN, P7 1411 DC
Phone: 35 206 2971
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?▲ Bullish(+3/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?6
Z-Score?100
Momentum?50
Short Sent.?29
Piotroski F-Score?1/9Weak
Altman Z-Score?33.06Safe
Confidence?55%Low
Short InterestHigh
Short % of Float?14.74%High
Short Interest?9.2M
Days to Cover?7.3
Free Float62.2M
Avg Daily Volume1.3M
Settlement Date2026-06-15
Financial Health
Current Ratio?9.74Strong
Quick Ratio?9.74Strong
Cash Ratio?6.79Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score58/100
P/E?N/A▾
P/B?5.84FAIR▾
Peers100
S&P32
P/S?172.21HIGH▾
Peers100
S&P3
P/FCF?N/A▾
EV/EBITDA?-16.0CHEAP▾
S&P97
EV/Sales?151.93HIGH▾
Peers100
S&P3
Returns & Efficiency
ROE?-32.0%WEAK▾
S&P6
ROA?-29.0%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-142187000
Enterprise Value?$3.4B
Fundamentals ratios updated end of day